Clinical Trial

AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 21, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
AK104, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to retain the efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety profile of the combination therapy. The aim of this study is to evaluate the efficacy and safety of AK104 with chemotherapy as neoadjuvant and adjuvant therapy for patients with resectable stage II-IIIA NSCLC.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-05-16.
Status change: Not Yet Recruiting → Recruiting 2024-02-19
Trial Details
NCT Number NCT05377658
Lead Sponsor Henan Cancer Hospital
Conditions Non-small Cell Lung Cancer
Enrollment 43 participants
Start Date 2022-07-26
Primary Completion 2024-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-02-21